
    
      A prospective, randomized study describing the safety and efficacy of the BAROSTIM NEO System
      in heart failure subjects with left ventricular ejection fraction equal to or less than 35
      percent. Seventy two subjects were randomized; 32 to the medical management arm and 40 to the
      device arm (38 implanted, 2 withdrawn). The study closed to new enrollments on January 31,
      2014. Subjects are in long-term follow-up and are required to have at least one annual visit.
      During the visit, there will be a physical assessment, a review of medications and serious
      adverse events.
    
  